Graham Capital Management L.P. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 16,600 shares of the biopharmaceutical company’s stock, valued at approximately $1,175,000.
A number of other hedge funds also recently made changes to their positions in GILD. Penserra Capital Management LLC increased its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $143,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 480 shares during the period. Sterling Investment Advisors Ltd. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $184,000. Finally, Washington Trust Bank increased its stake in shares of Gilead Sciences by 24.8% during the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 550 shares during the period. Hedge funds and other institutional investors own 76.23% of the company’s stock.
In other news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 458,486 shares of company stock worth $35,190,731. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.75 earnings per share. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.
GILD has been the topic of several research analyst reports. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Deutsche Bank reissued a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Credit Suisse Group set a $79.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Monday, August 28th. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. Finally, Berenberg Bank set a $86.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, August 29th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $85.22.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://sportsperspectives.com/2017/12/05/graham-capital-management-l-p-buys-new-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.